Literature DB >> 2159257

Evaluation of Bay R 3783 in rodent models of superficial and systemic candidiasis, meningeal cryptococcosis, and pulmonary aspergillosis.

R F Hector1, E Yee.   

Abstract

The triazole Bay R 3783 was compared with fluconazole, itraconazole, ketoconazole, and amphotericin B in rodent models of superficial and systemic candidiasis, meningocerebral cryptococcosis, and pulmonary aspergillosis. Overall, Bay R 3783 was comparable or slightly superior to fluconazole and markedly superior to itraconazole and ketoconazole in both survival and short-term organ load experiments in models of candidiasis and cryptococcosis but was less effective than amphotericin B. Of the antifungal agents tested, only Bay R 3783 and itraconazole showed any efficacy in the model of pulmonary aspergillosis.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2159257      PMCID: PMC171613          DOI: 10.1128/AAC.34.3.448

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  34 in total

1.  Comparison of itraconazole and ketoconazole in the treatment of experimental candidal vaginitis.

Authors:  J D Sobel; G Muller
Journal:  Antimicrob Agents Chemother       Date:  1984-08       Impact factor: 5.191

2.  Inhibition of sterol biosynthesis in Candida albicans by imidazole-containing antifungals.

Authors:  M S Marriott
Journal:  J Gen Microbiol       Date:  1980-03

3.  Itraconazole pharmacokinetics in the female genital tract: plasma and tissue levels in patients undergoing hysterectomy after a single dose of 200 mg itraconazole.

Authors:  E Larosa; G Cauwenbergh; P Cilli; R Woestenborghs; J Heykants
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  1986-10       Impact factor: 2.435

4.  Efficacy of UK-49,858 (fluconazole) against Candida albicans experimental infections in mice.

Authors:  P F Troke; R J Andrews; K W Brammer; M S Marriott; K Richardson
Journal:  Antimicrob Agents Chemother       Date:  1985-12       Impact factor: 5.191

5.  Comparison of itraconazole and fluconazole in treatment of cryptococcal meningitis and candida pyelonephritis in rabbits.

Authors:  J R Perfect; D V Savani; D T Durack
Journal:  Antimicrob Agents Chemother       Date:  1986-04       Impact factor: 5.191

6.  Treatment of cryptococcal meningitis in mice with fluconazole.

Authors:  E Palou de Fernandez; M M Patino; J R Graybill; M H Tarbit
Journal:  J Antimicrob Chemother       Date:  1986-08       Impact factor: 5.790

7.  Bifonazole and clotrimazole. Their mode of action and the possible reason for the fungicidal behaviour of bifonazole.

Authors:  D Berg; E Regel; H E Harenberg; M Plempel
Journal:  Arzneimittelforschung       Date:  1984

8.  R 51211 (itraconazole) therapy of murine cryptococcosis.

Authors:  J R Graybill; J Ahrens
Journal:  Sabouraudia       Date:  1984

9.  Fluconazole penetration into cerebrospinal fluid in humans.

Authors:  G Foulds; D R Brennan; C Wajszczuk; A Catanzaro; D C Garg; W Knopf; M Rinaldi; D J Weidler
Journal:  J Clin Pharmacol       Date:  1988-04       Impact factor: 3.126

10.  Itraconazole treatment of murine aspergillosis.

Authors:  J R Graybill; J Ahrens
Journal:  Sabouraudia       Date:  1985-06
View more
  10 in total

1.  Efficacy of ER-30346, a novel oral triazole antifungal agent, in experimental models of aspergillosis, candidiasis, and cryptococcosis.

Authors:  K Hata; J Kimura; H Miki; T Toyosawa; M Moriyama; K Katsu
Journal:  Antimicrob Agents Chemother       Date:  1996-10       Impact factor: 5.191

2.  In vitro and in vivo antifungal activities of ER-30346, a novel oral triazole with a broad antifungal spectrum.

Authors:  K Hata; J Kimura; H Miki; T Toyosawa; T Nakamura; K Katsu
Journal:  Antimicrob Agents Chemother       Date:  1996-10       Impact factor: 5.191

Review 3.  Strategies in prevention of invasive pulmonary aspergillosis in immunosuppressed or neutropenic patients.

Authors:  J Beyer; S Schwartz; V Heinemann; W Siegert
Journal:  Antimicrob Agents Chemother       Date:  1994-05       Impact factor: 5.191

4.  T-8581, a new orally and parenterally active triazole antifungal agent: in vitro and in vivo evaluations.

Authors:  A Yotsuji; K Shimizu; H Araki; K Fujimaki; N Nishida; R Hori; N Annen; S Yamamoto; H Hayakawa; H Imaizumi; Y Watanbe; H Narita
Journal:  Antimicrob Agents Chemother       Date:  1997-01       Impact factor: 5.191

5.  Urease expression by Cryptococcus neoformans promotes microvascular sequestration, thereby enhancing central nervous system invasion.

Authors:  Michal A Olszewski; Mairi C Noverr; Gwo-Hsiao Chen; Galen B Toews; Gary M Cox; John R Perfect; Gary B Huffnagle
Journal:  Am J Pathol       Date:  2004-05       Impact factor: 4.307

6.  Itraconazole for experimental pulmonary aspergillosis: comparison with amphotericin B, interaction with cyclosporin A, and correlation between therapeutic response and itraconazole concentrations in plasma.

Authors:  J Berenguer; N M Ali; M C Allende; J Lee; K Garrett; S Battaglia; S C Piscitelli; M G Rinaldi; P A Pizzo; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  1994-06       Impact factor: 5.191

7.  Evaluation of SCH51048 in an experimental model of pulmonary aspergillosis.

Authors:  R Allendoerfer; D Loebenberg; M G Rinaldi; J R Graybill
Journal:  Antimicrob Agents Chemother       Date:  1995-06       Impact factor: 5.191

8.  Use of DBA/2N mice in models of systemic candidiasis and pulmonary and systemic aspergillosis.

Authors:  R F Hector; E Yee; M S Collins
Journal:  Infect Immun       Date:  1990-05       Impact factor: 3.441

9.  In vitro antifungal activities and in vivo efficacies of 1,3-beta-D-glucan synthesis inhibitors L-671,329, L-646,991, tetrahydroechinocandin B, and L-687,781, a papulacandin.

Authors:  K Bartizal; G Abruzzo; C Trainor; D Krupa; K Nollstadt; D Schmatz; R Schwartz; M Hammond; J Balkovec; F Vanmiddlesworth
Journal:  Antimicrob Agents Chemother       Date:  1992-08       Impact factor: 5.191

10.  Positive interaction of nikkomycins and azoles against Candida albicans in vitro and in vivo.

Authors:  R F Hector; K Schaller
Journal:  Antimicrob Agents Chemother       Date:  1992-06       Impact factor: 5.191

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.